Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Colibactin-Producing Escherichia coli / E. coli pks are frequently detected in colorectal cancer (CRC) and exhibit procarcinogenic properties.
In mice, Colibactin-Producing Escherichia coli / E. coli pks + chronic infection decreases CD3 + and Cytotoxic T cell (CTL) and increases colonic inflammation
The colonization of Colorectal Cancer (CRC) patients by Colibactin-Producing Escherichia coli / E. coli pks + is associated with a decrease of tumor-infiltrating T lymphocytes (CD3 + T-cells)
Our findings suggest that Colibactin-Producing Escherichia coli / E. coli pks could pr…